UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
ANIMAL & VETERINARY HEALTH

Boehringer Ingelheim

B

Boehringer Ingelheim

Animal & Veterinary HealthIngelheim am Rhein, Germany
Visit Website

About Boehringer Ingelheim

Boehringer Ingelheim ranks among the largest research-driven pharmaceutical companies in the world and, uniquely for a business of its scale, remains wholly family-owned, having operated independently since its founding in Ingelheim am Rhein, Germany, in 1885. That private ownership shapes everything from its long investment horizon to its willingness to pursue complex biology that publicly listed peers may avoid.

Human and Animal Health

The company operates across two distinct businesses. Its human pharma division concentrates on respiratory diseases, cardiovascular and metabolic conditions, oncology, and immunology, with established medicines spanning COPD, heart failure, type 2 diabetes, and idiopathic pulmonary fibrosis. The animal health division is one of the largest in the world, covering livestock and companion animal health across a broad portfolio of vaccines and therapeutics, a segment reinforced by the 2017 asset swap with Sanofi that brought in Merial.

Global Research & Biopharmaceutical Manufacturing

Boehringer Ingelheim maintains a significant contract manufacturing presence alongside its own pipeline work. Its biopharmaceutical contract manufacturing organisation arm, among the longest-established in the industry, produces biologics for third-party clients as well as internal programmes. Research centres span Germany, Austria, the United States, China, and other locations, with the company consistently investing a substantial proportion of net sales back into research and development each year. Its pipeline spans small molecules, biologics, and cell and gene therapy technologies, reflecting a deliberate push into next-generation modalities. The group employs tens of thousands of people across more than 130 markets globally.

Headquartered in Ingelheim am Rhein, the company's independent status means it publishes net sales rather than stock-market results, with figures consistently placing it within the global top-ten pharmaceutical groups by revenue. Its therapy focus on diseases with significant unmet need, combined with a long-term ownership model, gives it a research culture oriented toward decade-spanning programmes rather than quarterly targets.

Further information is available at boehringer-ingelheim.com.

Similar Companies

More in Animal & Veterinary Health

I

International Animal Health Journal

Peer-reviewed publishing dedicated to the global animal health sector defines the work of International Animal Health Journal, a specialist B2B media title covering the regulatory, operational and commercial dimensions of veterinary medicines, veterinary devices and animal food. The journal provides industry professionals, contract service providers and regulatory affairs teams with substantive editorial on outsourcing in animal health, positioning it as a reference title for practitioners navigating a sector that operates under comparable compliance frameworks to human pharmaceuticals yet carries distinct regulatory requirements across major markets including the EU, US and UK. The publication maintains a structured editorial archive spanning ten volumes, with multiple issues produced per year, reflecting a sustained output that covers topic areas such as veterinary drug development, animal nutrition, supply chain management and the evolving regulatory landscape for veterinary products. Content is accessible through current features, archived issues and an alphabetically organised company profile directory, giving readers both timely industry news and a supplier intelligence resource. Although listed under Clinical Research in some classification systems, the journal's primary function is B2B trade media rather than clinical research provision. Its readership includes contract manufacturers, regulatory consultancies, veterinary device producers and animal food companies operating across companion animal, livestock and aquaculture segments. Further information is available at international-animalhealth.com.

View profile
A

Accord Healthcare

Accord Healthcare ranks among the fastest-growing generic and biosimilar medicines companies in Europe, distributing products across more than 80 countries and holding one of the largest market footprints of any European generic pharmaceutical business. Established as the European commercial arm of Intas Pharmaceuticals, an Indian pharmaceutical group headquartered in Ahmedabad, Accord operates its principal EMENA base from Uxbridge, United Kingdom, with additional commercial representation in Barcelona, Spain, and a growing network of affiliates across Eastern Europe. Therapeutic Portfolio and European Reach Accord's product portfolio is built around hospital and community settings across several key therapy areas. Its oncology and haematology range forms the largest segment of the business, complemented by lines covering autoimmune conditions and central nervous system disorders. The company has delivered successive year-on-year growth in the volume of medicines launched across European markets, with its most recent annual cycle yielding the largest portfolio rollout in the company's history. A dedicated European affiliate network, with national teams across Austria, Czech Republic, Finland, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Spain and Sweden, provides the commercial infrastructure to support hospital tenders and retail pharmacy channels simultaneously. Biosimilars, Animal Health and Sustainability Beyond small-molecule generics, Accord Healthcare operates at the higher-complexity end of pharmaceutical development through its biosimilars programme, where regulatory pathways and development timelines mirror those of originator biologics. This positions the company among a relatively small group of European generics firms capable of competing in both chemical and biological medicine categories. Accord also maintains an animal health division, extending the group's reach across the broader life sciences sector, alongside a patient advocacy group function that signals engagement with patient outcomes beyond the purely commercial. The company publishes environment, social and governance reporting in line with expectations from institutional partners and regulated healthcare customers across the European Union and beyond. Further information is available at accord-healthcare.com.

View profile
M

Merck (MSD)

Merck (MSD) created one of the most consequential vaccines in modern medicine, Gardasil, which targets the human papillomavirus strains responsible for the majority of cervical cancer cases worldwide. That achievement is emblematic of a company whose research has shaped global public health across more than a century of operation. Founded in 1891 as a subsidiary of the German Merck Group before becoming an independent entity, Merck operates under the MSD name outside the United States and Canada, giving it one of the more recognisable dual identities in the pharmaceutical industry. Oncology & Keytruda No single product better defines Merck's current position than Keytruda (pembrolizumab), the PD-1 inhibitor that has become the world's best-selling prescription medicine by revenue. Keytruda holds regulatory approvals across a broad range of tumour types, including non-small cell lung cancer, melanoma, head and neck cancers, and several others, cementing Merck's status as one of the dominant forces in cancer immunotherapy. The scale of the Keytruda programme, which spans hundreds of clinical studies in combination and monotherapy settings, reflects a research and development investment that runs to the tens of billions of dollars annually. Vaccines, Infectious Disease & Animal Health Beyond oncology, Merck maintains a substantial vaccines portfolio that extends from childhood immunisation programmes to travel medicine and hospital-acquired infections. The company's antiviral legacy includes longstanding contributions to HIV treatment and, more recently, Lagevrio (molnupiravir) for COVID-19. A dedicated Animal Health division, one of the largest in the world, supplies vaccines and medicines for both livestock and companion animals, underscoring the breadth of the Merck enterprise. Headquartered in Rahway, New Jersey, Merck trades on the New York Stock Exchange under the ticker MRK and employs tens of thousands of people across research, manufacturing, and commercial operations in more than 140 countries. Its pipeline spans infectious diseases, cardiovascular conditions, and several rare diseases, reflecting a deliberate strategy to extend leadership beyond immunology and oncology into areas of significant unmet medical need. Further information is available at merck.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy